Trump administration attacks on the National Institutes of Health mean biomedical research will become less ambitious, less ...
CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD -- Flexible Dosing and Extended Duration would be Important ...
Clearside Biomedical (CLSD) announced the receipt of the formal meeting minutes from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration relating to CLS-AX for the ...
March 06, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical ... Phase 3 program during our upcoming earnings call later this month.” Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results